The European Patent Office (EPO) takes a different approach to the US PTO when considering obviousness/inventive step in antibody cases. In this webinar, Mathys & Squire partners Martin MacLean and Hazel Ford discuss the arguments that are most likely to be effective when addressing inventive step objections at the EPO, focusing on the field of antibodies.